Medscape www.medscape.com

References for:
Steady-State Pharmacokinetics of Pravastatin in Children With Familial Hypercholesterolaemia

[Clin Drug Invest 24(2):113-120, 2004. © 2004 Adis Data Information BV]

  1. Singhvi SM, Pan HY, Morrison RA, et al. Disposition of pravastatin sodium, a tissue selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29: 239-43
  2. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990; 48: 201-7
  3. Pan HY, DeVault AR, Wang-Iverson D, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-35
  4. Pan HY, Triscari J, DeVault AR, et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991; 31: 665-70
  5. Pan HY, DeVault AR, Brescia D, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993; 31: 291-4
  6. Pan HY, Waclawski AP, Funke PT, et al. Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993; 27: 1029-33
  7. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-41
  8. Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatine and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66: 118-27
  9. De Jongh S, Lilien MR, op `t Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002; 40: 2117-21
  10. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39: 397-412
  11. Triscari J, O´Donnell D, Zinny M, et al. Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 1995; 35: 142-4
  12. De Jongh S, Lilien MR, Bakker HD, et al. Familial history of cardiovascular events and endothelial function in children with familial hypercholesterolemia. Atherosclerosis 2002; 163: 193-7
  13. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in childhood: a study in familial hypercholesterolemia heterozygotes and their siblings. Lancet. In press
  14. Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia: ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb 1993 Oct; 13 (10): 1404-11
  15. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996; 39: 867-71
  16. `t Jong GW, van der Linden PD, Bakker EM, et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol 2002 Jul; 58 (4): 293-7
  17. Kearns GL, Abdel-Raman SL, Alander SW, et al. Developmental pharmacology: drug disposition, action and therapy in infants and children. N Engl J Med 2003; 349: 1157-67
  18. Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 2000; 106 Suppl. 3: S128-38
  19. Kauffman RE. Clinical trials in children: problems and pitfalls. Pediatr Drugs 2000; 2: 411-8
  20. Kauffman RE. Drug trials in children: ethical legal and practical issues. J Clin Pharmacol 1994; 34: 296-9
  21. Koren G, Kearns GL, Reed M, et al. Use of healthy children as volunteers in drug studies: the ethical debate. Clin Pharmacol Ther 2003; 73: 147-52
  22. Fouchier SW, Defesche JC, Umans-Eckenhausen MAW, et al. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet 2001; 109: 602-15
  23. Friedewald WT, Levy RJ, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
  24. Validation report: quantitative determination of pravastatin and SQ-31906 in human serum by LC/MS/MS, PharmaLytics Inc, Saskatoon, Canada, 2001, BMS Document Control No. 920012813
  25. Triscari J, Swanson BN, Willard DA, et al. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993; 36: 263-5
  26. Wiegman A, Hutten BA, DeGroot E, et al. Statin therapy in hypercholesterolemic children: long-term efficacy and safety. In press
  27. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors; similarities and differences. Clin Pharmacokinet 1997; 32: 403-25
  28. Hedman M, Neuvonen PJ, Neuvonen M, et al. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther 2003; 74: 178-85
  29. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40